2 High-Yield Dividend Stocks to Buy and 1 to Avoid

The article favors Energy Transfer and Verizon as high-yield dividend investments while warning that Pfizer's 6.2% yield is vulnerable: Pfizer paid $9.7B in dividends against $9.1B of free cash flow last year, carries more than $60B of debt, and faces major patent expirations. Energy Transfer yields 6.4%, plans 3%-5% annual distribution growth, is spending up to $5.9B on growth capex, and trades at 8.5x forward EV/EBITDA amid rising AI data-center natural-gas demand. Verizon yields 5.5%, added 184,000 postpaid phone subscribers—its best quarter in five years—and trades at about 10x projected 2026 earnings.

Analysis

The differentiated ET thesis is not simply incremental data-center load; it is the value of contracted transport and processing capacity in constrained Texas corridors. If power developers secure interconnects faster than new pipeline capacity is permitted, ET can earn returns above its normalized fee-based profile through reservation fees, volumetric growth, and opportunistic basis/arbitrage capture. The near-term risk is that AI-load announcements remain speculative while project in-service dates slip, leaving growth capex ahead of cash generation; monitor signed take-or-pay commitments, not announced data-center MW.

PFE's key equity risk is a capital-allocation squeeze rather than an isolated patent-loss event. A dividend that competes with debt reduction and oncology-business investment can force a lower valuation multiple even if revenue declines are broadly anticipated, because management loses flexibility precisely when pipeline execution must be strongest. Over the next 6-18 months, a weaker-than-expected oncology launch trajectory, increased leverage, or any change in dividend-growth language would likely matter more than quarterly headline EPS; a material acceleration in deleveraging or credible late-stage trial wins would falsify the bearish view.

VZ's improving consumer metrics can support a modest rerating, but the larger upside requires fiber convergence to reduce churn and raise household economics without reigniting promotional spending. Frontier integration creates both the catalyst and the risk: operating synergies and wireless/fiber cross-sell are likely back-end loaded, while integration capex and competitive response from TMUS/T could pressure near-term free-cash-flow conversion. Consensus may be over-crediting the AI-fiber narrative before enterprise contract disclosures emerge; consumer convergence, not data centers, should drive the next two quarters.

Key Decisions for Investors

• Initiate a 6-12 month long ET / short AM relative-value position, sized 1:1 on beta-adjusted notional. ET offers broader exposure to Gulf Coast, Permian, and intrastate bottlenecks; AM is more dependent on Appalachian producer activity. Reassess if ET's new project backlog lacks firm contracts or growth capex rises without distributable-cash-flow coverage improvement.
• Maintain PFE as an underweight or establish a 9-12 month short versus a diversified large-cap pharma basket such as XLV, rather than outright sector short exposure. The catalyst path is guidance de-risking, pipeline updates, and capital-return scrutiny; cover on evidence of sustained deleveraging plus commercially meaningful oncology uptake that closes the funding gap.
• Buy VZ only on post-results confirmation that postpaid improvement is achieved without elevated retention spending; use a 3-6 month long VZ / short T pair to isolate execution versus broad telecom-rate sensitivity. Exit if service-revenue growth stalls, churn reverses, or Frontier-related capex pushes free-cash-flow expectations materially lower.
• Set an alert on Texas/ERCOT power interconnection and gas-pipeline permitting milestones over the next 1-3 months. A cluster of binding power and transport agreements is a stronger signal for ET than AI infrastructure headlines and would justify adding to the long; repeated power-project delays would argue for reducing exposure.